About US
Contact us
-
Additional testing completed on Alzheimer's disease biomarkerBiopharma company Navidea Biopharmaceuticals has announced the completion of a study into its new radiopharmaceutical NAV4694, which is designed to be used as a biomarker for visual detection of subs2013/1/18
-
EU signs off on Lilly's Amyvid, its diagnostic test for Alzheimer'sWhile Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, t2013/1/17
-
Armed with diagnostic, Biogen files for first-line Tysabri useIf persistence is a virtue, then Biogen Idec ($BIIB) is about as virtuous as they come. After years of safety problems, warnings, testing and retesting, the company has asked U.S. and European authori2013/1/17
-
Generic Reglan user can sue Pfizer for damagesIt's a state court ruling. It directly affects only one drugmaker. But the Alabama Supreme Court's decision to allow a patient to sue Pfizer ($PFE) for damages could ripple through the industry--and2013/1/15
-
Patients laud Lundbeck, Gilead, but give pharma's rep low marksPatients aren't happy with the pharma industry. A drumbeat of bad pharma news in 2012 took its toll on public opinion to the point where only one-third of patient groups gave drugmakers a thumbs-up.2013/1/15
-
India to hit Roche, BMS with compulsory licenses on 3 cancer drugsIndia is taking another swipe at Big Pharma. Three swipes, in fact: The government has started the process of granting three more compulsory licenses, this time on cancer treatments from Roche ($RHHB2013/1/14
-
Wockhardt receives approval for generic epilepsy tabletsWockhardt has announced the receipt of final approval for the marketing of a generic form of Lamotrigine, a form of medication which is used to treat epilepsy. The pharmaceutical and biotechnology2013/1/14
-
Lilly settles suit linking old miscarriage drug to breast cancerThe first court fight over the old miscarriage drug DES and alleged links to breast cancer didn't last long. On the second day of the trial, Eli Lilly ($LLY) settled with the four plaintiffs, who had2013/1/11
-
FDA orders dosage cuts on Sanofi's Ambien and its relativesWhat's one of the FDA's biggest worries about sleeping-pill safety? Hint: It's not your usual sort of adverse event. It's more like a bank shot off the human body than a hit to the body itself: Auto2013/1/11
-
Is rumored pharma target Bausch + Lomb aiming for an IPO instead?Big Pharma CEOs are throwing cold water on expectations for more medium-sized M&A this year. While analysts see promise for $10 billion deals, executives from Novartis ($NVS) to the newly indepen2013/1/10